FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
Season 7, Episode 47, Nov 14, 2022, 07:50 PM
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.